{"id":"W2269544826","doi":"10.1182/blood.v122.21.4175.4175","title":"An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Chronic lymphocytic leukemia; Internal medicine; Phases of clinical research; Oncology; Interim analysis; Refractory (planetary science); Pharmacology; Clinical trial; Leukemia; Cyclophosphamide; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003564136,0.0003711643,0.000802497,0.0005206974,0.00005545082,0.00008842034,0.0005562843,0.0001538754,0.00006728525],"category_scores_gemma":[0.000115716,0.0002719682,0.00002011768,0.00132211,0.0001464724,0.000651282,0.0001938624,0.0003184686,0.00001555846],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03190384,"about_ca_system_score_gemma":0.01607629,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03534026,"about_ca_topic_score_gemma":0.007974867,"domain_scores_codex":[0.9966193,0.0001627158,0.0007364021,0.0007297348,0.001057943,0.0006938993],"domain_scores_gemma":[0.9979579,0.00009710142,0.0002496645,0.00095704,0.0004603297,0.0002779044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02890148,0.3969035,0.5022845,0.002209003,0.001363198,0.001282389,0.01272639,0.001124915,0.03936261,0.00006250286,0.0002288349,0.01355063],"study_design_scores_gemma":[0.8295691,0.04875806,0.0898727,0.00114575,0.0002460981,0.00005767134,0.0004994518,0.02168956,0.007771576,0.000007615332,0.000005597598,0.000376806],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991341,0.0001065616,0.000006106728,0.00001536573,0.00001885826,0.008255984,0.00001221939,0.00005005323,0.0001938319],"genre_scores_gemma":[0.9985049,0.000008682267,0.0002132877,0.00003057077,0.00002910261,0.0008513068,0.0001362855,0.0000882188,0.0001375866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8006676,"threshold_uncertainty_score":0.9999732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02195042890963005,"score_gpt":0.3083522339784295,"score_spread":0.2864018050687994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}